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INTRODUCTION
Acquired  immunodeficiency  syndrome  is  caused  by  infection  with  human 
immunodeficiency virus type 1 and rarely type 2. The HIV pandemic has spread word 
wide since 1981.The first paediatric case of AIDS was reported to the centre for disease 
control  and  prevention  in  November  1982.  Since  then  HIV  infection  in  children 
represents a major setback to child health all over the world
Statement of problem and need of the study:
 India harbours world’s second highest number of HIV infected people (1). HIV 
infection  is  increasingly  becoming  a  prominent  cause  of  childhood  morbidity  and 
mortality in India.  Presently, 2,  02,000 children are living with HIV/AIDS in India. 
50% of these die within 2 years, constituting about 18% of 3.1 million AIDS deaths 
every  year  (2).  Despite  the  magnitude of  the problem, there is  paucity  of   data  on 
various issues in paediatric HIV infection from India.  In spite of that it is now well 
known that  the  epidemiological  and clinical  features  differ  greatly  from country  to 
country. The epidemiological features depend upon the social and cultural practices of 
those people which may again vary from region to  region. Opportunistic  infections 
(OIs) are an important cause of morbidity and mortality in children infected with HIV. 
The clinical features and opportunistic infections of HIV infection may depend on the 
organisms  and  parasites  endemic  in  that  country.  However,  few data  are  available 
regarding the overall prevalence, incidence and immunologic correlates associated with 
these diseases in the paediatric HIV population.  We undertook this study to identify the 
epidemiological,  clinical  background  and  its  correlation  with  CD4  values  and  the 
outcome of these children.
NATURAL HISTORY:
 Perinatal  transmission  is  the  main  mode  of  acquisition  of  HIV  infection  in 
children  and  also  via  blood  products  and  rarely  homosexual  or  heterosexual  in 
adolescents.  A  bimodal  distribution  of  disease  progression  is  seen  in  vertically 
transmitted HIV infection in children.  Early onset  of  symptoms at  younger than 12 
months of age with rapidly progressive disease and high mortality is observed in 10-25 
percent of infected infants. The majority of children with vertical transmission appear to 
have later onset symptoms and a better prognosis, with median time to development of 
AIDS of more than 5 years and survival of 6-9  years. Early age of disease onset is a 
marker of poor prognosis.
REVIEW OF LITERATURE
Most studies about paediatric HIV infection came from the developed countries. 
No such large scale information is  available in India.  HIV infection being a global 
emergency and spreading like a pandemic, the number of children affected with HIV 
infection is rapidly increasing. Most of the studies related to clinical profile of HIV 
came in the pre –ART era.
Highly  active  anti-retroviral  therapy  (HAART)  has  changed  the  face  of 
HIV/AIDS by leading to a dramatic decrease in HIV-related morbidity and mortality 
among those with access to therapy (3). Until recently, HAART was not accessible to a 
vast majority of the 5.1 million Indians living with HIV in India (4) primarily due to its 
high cost.   There was a significant decrease in the number of incident opportunistic 
infections, especially tuberculosis, in patients on HAART.
The advent of potent antiretroviral drugs has enabled transformation of human 
immunodeficiency virus (HIV) infection from a fatal to a chronic disease in developed 
countries (5).  However supportive care,  appropriate prophylaxis and management of 
infections are equally important. They are, in fact, the mainstay of therapy in countries 
such as ours where antiretroviral  therapy is  ill  affordable by most  patients (6).  The 
introduction of HAART become more available,  descriptions of  treated disease will 
include side  effects  and toxicities  of  therapy.   In  addition,  Indian children are  also 
afflicted  by  wasting,  malnutrition,  and  chronic  diarrhoeal  disease.  Appropriate 
immunizations,  prophylaxis  with  cotrimoxazole,  and  preventative  measures  such  as 
boiling water must be taken in order to avoid morbidity and mortality in children. Little 
is  known  about  the  natural  history  of  HIV  disease  in  Indian  children,  and  further 
research is needed.
The proposed study evaluates the clinical profile including opportunistic infections in 
relation to CD4 and determines the response to antiretroviral therapy.
Initial evaluation in HIV infected children includes detailed history to ascertain 
the  mode  of  transmission,  symptoms related  to  HIV and  HIV status  of  the  family 
members. The socioeconomic status and level of disease awareness in the caretakers 
should also be enquired into. A detailed physical examination including anthropometry, 
pulse oximetry, fundoscopy and neurodevelopment assessment should be carried out. 
Subsequently  if  feasible,  the  immune  status  and  viral  burden  should  be 
determined by estimation of CD4 counts and HIV RNA levels. Other laboratory tests 
include a complete hemogram including platelet count, liver and renal function tests, 
and X ray film of the chest, tuberculin test, stool examination, urine analysis and ECG. 
Immunoglobulin levels, echocardiogram, computerized tomography (CT) of the chest 
and plain head CT may be requested if indicated. 
After  clinical  and  immune  categorization  of  the  illness,  treatment  details  are 
planned and discussed with the caretakers. 
PRE ART EVALUATION AND FOLLOW UP
S.No. Evaluation Interval
1. Complete  history  and  physical 
examination
3 months
2. Review of systems 3 months
3. Development examination
  <  1 year age
   1-3 years
   > 3 years
3 months
6 months
Annually
4. Chest radiography Annually
5. Laboratory tests
Complete blood counts
CD4 / CD8
LFT
RFT
Urine analysis
3 months
3 months
3 months
Baseline and as indicated
Annually
6. Mantoux test Annually
7. Referrals
Ophthalmology
Cardiology
Annually
If indicated
Antiretroviral therapy: 
Antiretrovirals  can  be  classified  as  nucleoside  reverse  transcriptase  inhibitors 
(NRTIs),  non-nucleoside  reverse  transcriptase  inhibitors  (NNRTIs)  and  protease 
inhibitors (PIs). As many as 13 antiretroviral agents are currently FDA approved for 
treatment of HIV infection (5). NRTIs were the first drugs to be used and are the least 
expensive. NNRTIs are increasingly being evaluated in pediatric treatment protocols. 
They are not associated with significant interactions with food; need to be taken once or 
twice  daily  and  freely  cross  the  blood  brain  barrier.  Protease  inhibitors  are  very 
efficacious but expense and side effects are major limiting factors. Details of commonly 
used drugs are listed in Table 1. Certain new drugs including NRTIs such as Abacavir, 
Adefovir and NNRTIs such as Efavirenz are also being evaluated in children (5). 
COMMONLY USED ANTIRETROVIRAL IN CHILDREN
Drug Dose Side effects Trade name Practical points
                                                          NRTIs
Zidovudine 
(AZT, 
ZDV)
Neonates-2 
mg/kg  6 
hourly 
children 
90-180 
mg/m2  6-8 
hrly
Anemia,
myopathy
Zidovir  soln. 
50mg/ml 
100mg 
capsules, 
300  mg 
tablets
Good  CNS 
penetration 
Decrease  dose  if 
there  is  bone 
marrow suppression
Didanosine 
(ddI)
90mg/m3  12 
hrly
neuropathy, 
pancreatitis,
abd. pain ,
diarrhea
Administer  empty 
stomach,  space 
administration  with 
protease inhibitors
Lamivudine 
(3TC)
4  mg  /kg  12 
hrly
Pancreatitis, 
neuropathy, 
neutropenia
Lamivir  soln 
50 mg / 5 ml 
Tablets  150 
mg 
Prevents  emergence 
of  zidovudine 
resistance
Stavudine 
(d4T)
1mg  /  kg  12 
hrly
Headache,GI 
upset, neuropathy
Stavir 
capsule  30 
mg, 40 mg
Should  not  be 
combined with AZT
                                                             NNRTIs
Nevirapine 
(NVP)
120-200  mg/
m3 12 hrly
Skin  rash, 
stevenjohnson 
syndrome
Nevimune 
200  mg 
tablets
Start  with  120 
mg/m2  for  2  wks 
and then increase to 
full  dose  if  no  side 
effect
                                                       Protease Inhibitors
Ritonavir 400mg/m2/12 
hrly
Badtaste,vomiting, 
nausea, diarrhea
Norvir  80 
mg  /  ml, 
capsules  100 
mg
Start  with  250 
mg/m2  and  then 
increase  give  with 
meals
Nelfinavir 20-30 mg / kg 
8 hrly
Diarrhoea, 
abdominal pain
Give with meals
Indinavir 50mg/m2  8 
hrly
Nephrolithiasis Empty  stomach, 
adequate hydration
Saquinavir 50  mg  /  kg  / 
hrly
Diarrhoeal 
headache
Fortovase 
softgel  cap 
capsules
Antiretroviral  therapy  provides  significant  clinical  benefit  in  HIV  infected 
children  with  immunologic  or  clinical  symptoms  of  HIV infection  with  substantial 
improvements in neurodevelopment, growth, immunologic and/or virologic status (7). 
The  efficacy  of  antiretroviral  therapy  in  asymptomatic  children  has  not  been 
demonstrated.  However  given  the  pathophysiologic  sequence  of  events  in  HIV 
infection, early aggressive therapy may help in preservation of the immune system and 
minimization of the risk of antiviral resistance. Moreover it has been found that infants 
and children have higher levels of plasma virus and more rapid disease progression as 
compared to adults (5). 
Therefore the Working Group on Antiretroviral Therapy and Medical Management 
of  HIV-Infected  Children  has  proposed  the  following  indications  for  initiation  of 
antiretroviral therapy (8). 
• Clinical symptoms associated with HIV infection (Categories A, B, C) 
• Evidence of immune suppression (Immune category 2 or 3) 
• Age < 12 months-regardless of clinical, immunologic or virologic status. 
• For asymptomatic  children > 1 year with normal immune status the preferred 
approach is to offer therapy to all. Alternatively treatment may be deferred and 
the virologic, immunologic and clinical status monitored. Therapy is initiated in 
the following circumstances. 
• High or increasing HIV RNA copy number. 
• Rapidly declining CD4 count/CD4 % approaching immune  category 2. 
• Development of clinical symptoms. 
To simplify, the recent consensus is to use antiretrovirals in all HIV infected children 
irrespective of clinical, immunologic and virologic status (5). 
Regimen of anti retroviral drugs : 
• Preferred regimen  :two NRTI plus one PI
• Recommended dual NRTI combinations: ZDV+ddI, ZDV+3TC, d4T+ddI, 
d4T+3TC,
• Protease inhibitors: RTV;NFV; IDV;SQV
• Alternate regimen:NVP+2NRTI
• Secondary Alternate regimen:2NRTI
• Not recommended: Any Monotherapy, d4T+ZDV,
As in adults,  the combination of two NRTIs and one protease inhibitor is the 
preferred regime and comprises what is known as Highly Active Antiretroviral Therapy 
(HAART). Recommended NRTI combinations are zidovudine (ZDV) with didanosine 
(ddI) or ZDV and lamivudine (3TC). Limited data are available for combinations of 
stavudine (d4T) and ddI, d4T and 3TC, and ZDV and zalcitabine (ddC). Combinations 
of  d4T  with  ZDV  and  ddC  with  ddI/d4T/3TC  should  be  avoided.  The  protease 
inhibitors currently approved for infants and children are nelfinavir  or ritonavir  and 
indinavir for those who can swallow capsules (8). 
Nevirapine  with  two  NRTIs  is  an  alternative  and  cheaper  regime.  The 
combination of only two NRTIs though of limited benefit can be offered when cost, 
non-availability  or  toxicity  precludes  the  use  of  protease  inhibitors  (8).  This 
combination  results  in  significant  clinical  improvement,  virologic  and  immunologic 
recovery and improves the quality of life although for a short time (7). The risk of 
resistance  with  such  therapy  in  children  is  of  a  lesser  concern,  as  they  in  usual 
circumstances do not pass on the resistant strains to others. 
Monotherapy with any drug should be employed only for prevention of perinatal 
transmission and not for treatment purposes (8). 
Monitoring and follow up: 
On follow up the child should be evaluated for clinical improvement, compliance, 
adverse drug reactions as well as for rise in the CD4 counts and suppression of HIV 
RNA levels (Table 3).  CD4 counts are estimated every three months.  Plasma RNA 
determinations 4 weeks after initiating therapy and then 3 monthly are advocated. With 
a combination of two NRTIs a five-fold reduction of HIV RNA levels by 8-12 weeks is 
expected (8). With the standard regime of 2 NRTIs and a protease inhibitor, a ten-fold 
reduction is expected by 8-12 weeks and levels should be undetectable by 4-6 months 
(8).  However  since  perinatally  infected  children  have  high  baseline  RNA  levels, 
complete  suppression  is  often  not  achievable  unlike  adults  (5).  In  case  of  lack  of 
optimal response, compliance, dosing schedule and possible drug interactions should be 
reviewed. If these are satisfactory and the lack of response is persistent,  antiretroviral 
resistance  should  be  suspected.  Molecular  techniques  to  identify  mutations  for  the 
confirmation of resistance to antiretroviral drugs are under evaluation. 
Madhivanan  et  al  (9)  and  Merchant  (10)  and  his  colleagues  in  their  studies 
conducted  in  India   in  2001  reported  that,  Vertical  transmission  is  responsible  for 
between  67  and  87  per  cent  of  paediatric  HIV infection,  with  the  majority  of  the 
remaining infections occurring due to blood transfusions. 
The clinical  features  of  HIV infection in  children are  different  from those  in 
adults. Perinatally infected children become symptomatic by five years of age.  Failure 
to  thrive  is  the  most  common  clinical  condition  associated  with  HIV  infection  in 
children(9,10) Pulmonary and extrapulmonary tuberculosis was consistently the most 
frequent opportunistic infection reported in two major studies in Indian children with 
HIV. (9, 10)
Opportunistic infections (OIs) are an important cause of morbidity and mortality 
in children infected with HIV. However, few data are available regarding the overall 
prevalence, incidence and immunologic correlates associated with these diseases in the 
paediatric HIV population. 
CD4 T-lymphocyte is the immune system cell that HIV infects and destroys, and 
the CD4 count roughly reflects the state of the immune system. Low CD4 T-cell counts 
are considered to be a marker of the progression of HIV infection and AIDS, and have 
been called the 'signature' of HIV (Balter 1997). Since HIV was first claimed to be the 
cause of AIDS in 1984, the CD4 count has been widely used to make treatment and 
diagnostic  decisions,  but  the  use  of  the  CD4  count  has  been  controversial,  and 
recommendations regarding how to use them have changed many times over the years.
CD4 estimation is the backbone of AIDS control program in developing nations. It has 
been studied as a marker of progression of HIV infection and as a measure of relative 
risk of developing opportunistic infections.HIV weakens the immune system so that 
opportunistic infections develop. Chakravarty  et al, 2006 Indian study,(11)has showed 
children with opportunistic infection have lower CD4 values as compared to children 
without  opportunistic  infection  . Ylitalo  et  al    (12)  h  as  also  proved  the  same. 
Chakravarthy et al., 2006 Indian study (11) has showed CD4 percentage declining with 
progression in the WHO clinical stages of HIV infection.
The progression of disease is related to gradual disruption of lymph node 
architecture  leading  to  high  levels  of  viremia  and  disappearance  of  CD4  cells 
during later stages of disease. However, further studies of CD4 counts in relation 
to antiretroviral therapy in children needs to be done.
Fox- Wheeler et al  (13) in his studies has showed ,HIV is associated with malnutrition. 
Similar  observation  has  been  reported  in  other  studies  as  well, Shah  and  Bachou, 
Uganda, 2006. (14,15 )
Agarwal, et al (16) in his studies conducted in Banaras Hindu university in 2005 
has  showed, CD4% correlated significantly with the deterioration of the WHO clinical 
stages and increasing grades of protein energy malnutrition .
Protein energy malnutrition leads to depletion of CD4 counts,  and this is 
perhaps  exacerbated  by  the  presence  of  HIV  infection.  Protein  energy 
malnutrition impacts the course of HIV by contributing to immuno-suppression.
Anniek et al (17) in his studies compared paediatric HIV in African settings to 
paediatric  HIV  in  Western  settings  and  to  adult  HIV  in  African  settings.  Several 
differences in diagnostic, clinical, immunological and virological characteristics were 
identified, as well as variations in the most influential factors for disease progression 
and  response  to  ART.  Environmental  factors  may  influence  disease  progression, 
mortality, loss to follow-up, adherence and the need to adapt the regimen. The selected 
African paediatric programs recorded a higher increase in median CD4-percent than the 
selected  Western  paediatric  programs and  a  higher  increase  in  CD4-count  than  the 
selected  African  adult  programs.  Compared  to  the  adult  programs,  the  African 
paediatric  programs had lower  drop-out  rates,  higher  reported adherence levels  and 
comparable mortality rates. The Western paediatric programs, however, had the lowest 
mortality rates.
Pulmonary and extra pulmonary tuberculosis was consistently the most frequent 
opportunistic  infection  reported  in  two  major  studies  in  Indian  children  with  HIV. 
Although  frequencies  differed,  oral  candidiasis,  hepatosplenomegaly,  recurrent 
respiratory  tract  infection,  Pneumocystis  carinii pneumonia,  chronic  lung  disease, 
persistent generalized lymphadenopathy, chronic diarrhoea, pyrexia of unknown origin, 
chronic  hypertrophic  parotitis,  chronic  otorrhoea,  bacterial   skin infection,  and PPE 
have also been reported in these studies.
PCP however, was seen much less commonly in Indian cohorts (3.4- 3.9%) than 
Western  cohorts  where  it  is  the  most  common  AIDS  diagnosis  in  infancy  (18). 
Pneumocystis jerovecii causes severe pneumonia in patients with AIDS. Occurrence of 
PCP establishes the diagnosis of AIDS (19) and it is the most common AIDS-defining 
illness in the developed world. In India, however, very low rates (0.7 to 7%) 4, of PCP 
have  been  reported.  Some  reasons  for  this  could  be  the  predominance  of  other 
pulmonary diseases like TB, and due to under diagnosis of incident cases.. According to 
a large natural history study, Indian patients with PCP were 4.5 times more likely to die 
than patients without PCP. Median survival after diagnosis of PCP in this study was 24 
months.
Bacterial pneumonia was reported as an opportunistic infection in 1.8 per cent of a 
large southern Indian cohort of HIV-positive patients. Similar to HIV negative individuals, 
the  most  common  causes  of  acute  community  acquired  pneumonia,  are  encapsulated 
bacteria,  Streptococcus  pneumonia  and  Haemophilus  influenzae.  Rates  of  bacterial 
pneumonia can be up to 25-fold higher among HIV infected children than in the general 
community.  Although bacterial  pneumonias can occur relatively early in the course of 
HIV, frequency of occurrence is inversely proportional to CD4 count.
Oral  candidiasis  occurs  frequently  in  children  with  HIV infection;  it  has  been 
reported as one of the most common HIV-associated condition, occurring in up to 70 per 
cent of cases. The pseudo membranous “white patches” variant of candidiasis is associated 
with  more  severe  immunosuppression  than  the  erythematous,  hyperplastic  or  angular 
chelitis types. 
Cryptococcal  meningitis  (CM)  has  been  reported  as  the  most  common 
opportunistic infection of the CNS of Indian children with HIV. Poor prognostic factors 
for  CM include positive blood cultures,  altered mental  status,  CSF antigen titre  above 
1:1024, positive CSF India ink smear, CSF white cell count below 20cells/cu.mm, and 
elevated  CSF  pressures.  Gold  standard  diagnosis  of  CM  requires  demonstration  of 
organism in CSF. 
TB  meningitis  in  HIV  children  is  different  from  HIV  negative.  Cognitive 
dysfunction is more common, and pathological features demonstrate reduced and atypical 
inflammatory  responses,  and  extensive  vasculopathy.  There  is  absence  of  minimal 
meningeal  enhancement  and  absence  of  communicating  hydrocephalus  on  computed 
tomography (CT) scan in HIV-positive patients. As expected, mortality is higher in the 
HIV positive group.
Chronic diarrhoea is a major problem in HIV infected children, affecting up to 76 
per cent of those with AIDS. It  is associated with a 3.3 fold increased risk of disease 
progression.  In  reports  from  north,  south  and  east  India,  Isospora  belli  and 
Cryptosporidium parvum were the two most common causes of chronic diarrhoeal disease 
in  HIV  infected  children.  Blastocystis  hominis,  Strongyloides  stercoralis,  Entamoeba 
histolytica,  Giardia lamblia, enteropathogenic  Escherichia coli,  Enterocytozoon bieneusi 
and Campylobacter jejuni are other causative agents of diarrhoea in Indian patients with 
HIV. There was no geographic pattern to the frequency of organisms.
A variety of ocular conditions associated with AIDS in India have been reported: 
extensive blepharitis and spontaneous lid ulcer, extensive molluscum contagiosum CMV 
retinitis, herpes simplex keratitis, bilateral papilloedema with cryptococcal meningitis. The 
most common ophthalmic opportunistic infection in India is CMV retinitis, which almost 
always occurs in patients with CD4 counts <50 cells.
With the availability of antiretroviral therapy at lower cost, the clinical profile of 
HIV disease is now changing to include drug-related  toxicities and immune reconstitution 
syndrome.
Immune  reconstitution  is  of  increasing  concern  in  the  developing  world  as 
HAART becomes more available in settings where opportunistic infections, especially 
TB, are abundant. The clinical presentation of IRS is an apparent clinical deterioration 
of the patient despite treatment. This could indicate a successful, though undesirable, 
effect  of  HAART,  or  instead,  treatment  failure  and  subsequent  progression  of  the 
opportunistic infection. 
AIM OF THE STUDY
1. To study the clinical profile of pediatric HIV. 
2. To correlate the clinical profile with CD4 values.
3. To analyse the outcome and the  response to ART in relation to CD4
MATERIALS & METHODS
 Setting
Study was conducted in Institute of child health and research centre-
Government Rajaji hospital, Madurai.
 Collaboration Departments
The study was done in collaboration with ART centre, Department of 
Microbiology, Department of Pathology , GRH,Madurai.
 Ethical committee
Approval for the study was obtained from The Ethical committee of Govt. 
Rajaji Hospital. 
  Study design
         Prospective cross sectional analytical study
 Study period
          The study period was from June 2006-July 2008
 Sample size
A total of 355 children which included all children enrolled in ART centre, 
Government Rajaji Hospital, Madurai.            
Inclusion criteria:
1. Newly  diagnosed HIV positive children >18 months up to 15 
Years.
  2. Children < 18 months with positive DNA PCR
Exclusion criteria:
  1. Children previously on ART
The study was conducted prospectively from June 2006 to July 2008 (26 months) 
and  included  children  (aged  1  month  to  15  years)  admitted  consecutively  to  the 
pediatric wards with the diagnosis of HIV infection. Children were tested for HIV if 
they had one or more of the following manifestations: prolonged unexplained fever, 
chronic  diarrhea,  generalized  lymphadenopathy,  recurrent  systemic  infections, 
septicemia or failure to thrive. Informed consent was obtained from the parent/guardian 
for the HIV testing with appropriate pre and post-test counseling. ELISA testing for 
HIV antibodies was performed for establishing the diagnosis. If detected to be positive, 
confirmation was done by two more ELISA tests. Children less than 18 months of age 
underwent confirmation by DNA-PCR testing. HIV status of the parents and siblings of 
the affected children was also requested (after appropriate counseling).
Definitions of Clinical factors studied :
Asymptomatic :   
No HIV related symptoms reported and no signs on examination.
Persistent generalized lymphadenopathy (PGL) :
Swollen or enlarged lymph nodes > 1 cm at two or more non contiguous sites, 
without known cause.
Unexplained persistent hepatosplenomegaly :
Enlarged liver and spleen without obvious cause
Papular pruritic eruptions :
Papular pruritic vesicular lesions. Scabies and insect bites should be excluded.
Fungal nail infections :
Fungal paronychia (painful, red and swollen nail bed) or onycholysis (painless 
separation of the nail from the nail bed).  Proximal white subungual onchomycosis is 
uncommon without immunodeficiency.
Angular cheilitis :
Splits or cracks on lips at the angle of the mouth with depigmentation usually 
responding to antifungal treatment but may occur.
Lineal Gingival Erythema : (LGE)
Erythematous band that follows the contour of the free gingival line ; may be 
associated with spontaneous bleeding.
Extensive wart virus infection :
Characteristic warty skin lesions ; small fleshy grainy bumps, often rough, flat on 
sole of feet (plantar warts),  facial, more than 5% of body area or disfiguring.
Extensive molluscum contagiosum infection :
Characteristic skin lesions : small flesh coloured, pearly or pink, dome-shaped or 
umbilicated growths, may be inflamed or red ; facial, more than 5% of body area or 
disfiguring.
Recurrent oral ulcerations (two or more in six months) :
Aphthous ulceration, typically with a halo of inflammatio and yellow grey pseudo 
membrane.
Unexplained parotid enlargement :
Asymptomatic  bilateral  swelling that  may  spontaneously  resolve  and recur,  in 
absence of other known cause, usually painless.
Herpes zoster :
Painful  rash  with  fluid  filled  blisters,  dermatomal  distribution,  can  be 
haemorrhagic on erythematous background, and can become large and confluent. Does 
not cross the midline.
Recurrent upper respiratory tract infection (URTI) :
Current event with atleast one episode in past 6 months. Fever with unilateral face 
pain and nasal  discharge (sinusitis)  or  painful  swollen eardrum (ortitis  media),  sore 
throat with productive cough (bronchitis) sore throat (pharyngitis) and barking croup 
like cough (LTB). Persistent or recurrent ear discharge.
Unexplained moderate malnutrition :
Weight loss : low weight for age, up to 2 standard deviations (SDs), not explained 
by poor or inadequate feeding and or other infections and not adequately responding to 
standard management.
Confirmed by documented loss of body weight of -2 SD, failure to gain weight on 
standard management and no other cause identified during investigation.
Unexplained persistent diarrhoea :
Unexplained persistent (14 days or more) diarrhoea (loose or watery stool, three 
or more times daily), not responding to standard treatment). Confirmed  by  stools 
observed and documented as unformed. Culture and microscopy reveal no pathogens.
Unexplained persistent fever (intermittent or constant, for longer than one month)
Reports of fever or night sweats for longer than one month, either intermittent or 
constant,  with  reported  lack  of  response  to  antibiotics  or  anti  malarials.   No  other 
obvious foci of disease reported or found on examination.  Malaria must be excluded in 
malarious areas. Confirmed by  documented  fever  of  >  37.5  C with  negative  blood 
culture, negative malaria slide and normal or unchanged CXR, and no other obvious 
foci of disease.
Oral Candida : (outside first 6-8 weeks of life)
Persistent or recurring creamy white to yellow soft small plaques which can be 
scraped off (pseudomembranous), or red patches on tongue, palate or lining of mouth, 
usually painful or tender (erythmatous form).Confirmed by microscopy or culture.
Oral hairy leukoplakia :
Fine small linear patches on lateral borders of tongue, generally bilaterally, which 
do not scrape off.
Lymph node TB :
Non acute, painless “cold” enlargement of lymphnodes, usually matted, localized 
to one region.  May have draining sinuses. Response to standard anti-TB treatment in 
one month. Confirmed  by  histology  or  fine  needle  aspirate  for  Ziehl  Neelsen 
stain/Culture.
Pulmonary TB :
Nonspecific  symptoms,  eg.  Chronic  cough,  fever,  night  sweats,  anorexia  and 
weight loss. In the older child also productive cough and haemoptysis. Abnormal CXR. 
Response to standard anti – TB treatment in one month. Confirmed  by  positive 
sputum smear or culture.
Severe recurrent presumed bacterial pneumonia :
Cough with fast breathing, chest indrawing, nasal flaring, wheezing and grunting. 
Crackles or consolidation on auscultation. Responds to course of antibiotics. Current 
episode plus one or more in previous 6 months.
Confirmed  by  isolation  of  bacteria  from  appropriate  clinical  specimens  (induced 
sputum, BAL, lung aspirate).
Acute necrotizing ulcerative gingivitis or stomatitis, or acute necrotizing ulcerative 
periodonitis.
Severe pain, ulcerated gingival papillae, loosenig of teeth, spontaneous bleeding, 
bad odour, and rapid loss of bone and or soft tissue.
Symptomatic LIP : Diagnosed  by  CXR  :  bilateral  reticulo  nodular  interstitial 
pulmonary infiltrates present for more than two months with no response to antibiotic 
treatment and no other pathogen found.  Oxygen saturation persistently < 90%. May 
present  with  corpulmonale  and  may  have  increased  exercise  induced  fatigue. 
Characteristic histology.
Chronic HIV associated lung diseases (including bronchiectasis)
History  of  cough  productive  of  copious  amounts  of  purulent  sputum 
(bronchiectasis  only),  with  or  without  clubbing,  halitosis,  and  crepitations  and  or 
wheezes on auscultation.
Confirmed by  CXR may  show honeycomb appearance  (small  cysts)  and  /  or 
persistent areas of opacification and / or widespread lung destruction, with fibrosis and 
loss of volume.
Unexplained  anaemia  (<8g/dl)  or  neutropenia  (<1000/mm3)  or  chronic 
thrombocytopenia (< 50000/mm3):No presumptive diagnosis. Diagnosed  on 
laboratory testing, not explained by other non HIV conditions, or not responding to 
standard therapy with haematinics, antimalarials or antihelminthics as outlined in MCI.
Unexplained  severe  wasting,  stunting  or  severe  malnutrition (not  adequately 
responding to standard therapy.)
Persistent  weight  loss  not  explained  by  poor  or  inadequate  feeding,  other 
infections  and  not  adequately  responding  in  two  weeks  to  standard  therapy. 
Characterised by : visible severe wasting of muscles with or without oedema of both 
feet, and or weight for height of 3 SDs as defined by WHO IMCI guidelines.
Confirmed by documented weight loss of > -3 SD +/- oedema
Pneumocystis pneumonia PCP :
Dry cough, progressive difficulty in breathing, cyanosis, tachypnoea and fever ; 
chest indrawing or stridor.  (Severe or very severe pneumonia as in IMCI). Usually of 
rapid onset especially in inflants under six months of age.  Response to high dose co-
trimoxazole +/- prednisolone. Confirmed  by  :  CXR  typical  bilateral  perihilar 
diffuse infiltrates ; microscopy of induced sputum or BAL or NPA, or histology of lung 
tissue.
Recurrent severe presumed bacterial infection, eg. Empyema, pyomyositis bone or 
joint infection, meningitis but excluding pneumonia.  Fever  accompanied  by 
specific symptoms of signs that localize infection.  Responds to antibiotics.  Current 
episode plus one or more in previous 6 months. Confirmed  by  culture  of 
appropriate clinical specimen.
Chronic herpes simplex infection :  (orlabial or cutaneous of more than one month’s 
duration or visceral at any site). Severe and progressive painful oralabial, genital, or 
anorectal lesions caused by HSV infection present for more than one month. Confirmed 
by culture and / or histology
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs). Chest  pain 
and dysphagia (difficulty in swallowing), odynophagia (pain on swallowing food and 
fluids) or retrosternal pain worse on swallowing (food and fluids) responds to specific 
treatment.  In young children, suspect particularly if oral candida observed and food 
refusal occurs and / or difficulties / crying when feeding. Confirmed  by  macroscopic 
appearance  at  endoscopy,  microscopy  of  specimen  from  tissue  or  macroscopic 
appearance at bronchoscopy or histology.
Extrapulmonary / disseminated TB :
Systemic illness usually with prolonged fever, night sweats, weight loss. Clinical 
features of  organs involved,  eg.  Sterile pyuria,  pericarditis,  ascites,  pleural  effusion, 
meningitis, arthritis, orchitis.  Respods to standard anti TB therapy. Confirmed  by 
positive  microscopy  showing  AFB  or  culture  of  Mycobacterium  tuberculosis  from 
blood or other relevant specimen except sputum or BAL, biopsy and histology.
IAP (Indian Academy of Paediatrics) grading of malnutrition :  
Grade I   -   71-80% of expected weight for age
Grade II  -  61-70% of expected weight for age
Grade III -  51-60% of expected weight for age
Grade IV -  less than 50% of expected weight for age.
Clinical  details  were  recorded  including  demo-graphic  details,  possible 
modes of transmission, presenting symptoms, nutritional status and opportunistic 
infections  at  the  time  of  presentation.  Opportunistic  infections  were  diagnosed 
using the standard protocol. Baseline CD4 lymphocyte counts were determined by 
FACS count.  Based on the clinical presentations,  the children were categorized 
into various WHO clinical stages (I to IV) (3). Weight for age was used to grade 
them (IAP classification) for protein energy malnutrition (4). They were further 
classified  based  on  CD4%  values  in  accordance  with  WHO  classification  of 
immunodeficiency (3). CD4 cell count varies with age so CD4% was used to define 
immunologic  category  (5).  Antiretroviral  therapy  was  started  according  to 
National  AIDS  Control  Organization  (NACO)  guidelines  (3).  Patients  were 
followed up every month and CD4 counts were repeated at 6 monthly interval.
 Pulmonary  tuberculosis  was  diagnosed  on  the  basis  of  positive  Manteoux  test 
(erythema and induration 5 mm), chest radiograph, screening of family members for 
tuberculosis,  nonresponse  to  conventional  antibiotic  therapy  and  good  response  to 
antitubercular  drugs. Tuberculosis  was  managed  as  per  RNTCP  guidelines. 
Additionally, tuberculosis of the lymph nodes was diagnosed on the basis of aspiration 
cytology or excision biopsy while abdominal tuberculosis was diagnosed on the basis of 
findings on  ultrasonography of the abdomen and also barium studies.
 HIV encephalopathy was diagnosed on the basis of clinical  features,  neuroimaging 
findings,  CSF (cerebrospinal fluid) studies and exclusion of other processes causing 
similar clinical manifestations. HIV cardiomyopathy was recognized by virtue of the 
color Doppler findings. Patients were treated symptomatically based on their clinical 
presentation.  Opportunistic  infections  were  treated  adequately  and  appropriate 
prophylaxis was administered for prevention of recurrence of opportunistic infections. 
(8).All  exposed infants were prescribed cotrimoxazole prophylaxis from 6 weeks of 
age. Older children were prescribed cotrimoxazole only if ART eligibility criteria were 
met. First-line drugs include zidovudine or stavudine plus lamivudine plus nevirapine or 
efavirenz. Where  possible, children with hemoglobin levels less than 10 g/dL were not 
prescribed  zidovudine.  Nevirapine  was  used  preferentially  in  all  children,  while 
efavirenz was reserved for those requiring concurrent treatment with rifampicin or not 
tolerating nevirapine. After treatment initiation, patients were under observation  for 2 
weeks.  At  each  visit,  peer  counselor  &  ART  counselor   performs  an  adherence 
assessment.   These  adherence  counselling  sessions  were  also  used  to  provide  and 
education regarding drug adverse effects.
All clinical data pertaining to the study subjects were entered in the EXCEL 
worksheet at every follow up visit .Data were then analysed. One way ANOVA 
(analysis of variance) test was used to compare the means and Fisher’s exact/ Chi 
square test for categorical variables. 
 Changes in the weight, CD4 count, CD4% at the baseline and at 6 months 
follow up visit were compared using paired t test. 
RESULTS
During  the  study  period,  355  children  were  screened  positive  for  HIV 
infection. Their demographic profile is given in Table I.
 The  mean age  of  first  presentation  was  4.5  years  (0-15  years).  Vertical 
transmission was the assumed mode of transmission in 97% children in view of 
maternal seropositivity. Blood transfusion was considered the cause of infection in 
1 child (received transfusion from his  distant  relative).  Multiple  injections was 
presumed mode in 2 children (history of injection at village hospitals). 
 Fever was the most common presenting symptom (42%), followed by cough 
(38%),  chronic  diarrhea  (26%),  skin  manifestations  (26%),  generalized 
lymphadenopathy(22%)  hepato-splenomegaly  (22%)  and  other 
manifestations(12%).
 One  third  of  the  children  were  asymptomatic.  CD4%  declined  with 
deterioration  of  WHO clinical  stages  of  the  disease  (Table  II).  Protein  energy 
malnutrition was present in 82% children. Mean CD4 percentage was 42.6%±10.7 
in children without malnutrition (18%). Mean CD4 percentage was 18%±9.7 in 
children with some degree of  malnutrition (82%) The various grades of protein 
energy malnutrition with their corresponding mean CD4 values are given in Table 
III. The correlation of severity of malnutrition with decline in CD4 percentage was 
significant (P<0.05). 
One hundred and twenty one children (30%) had opportunistic infections at 
the time of evaluation. Patients with opportunistic infections had lower CD4 values 
(12.9%±9.4) as compared to patient without any opportunistic infections (28.4%
±8.6). Tuberculosis was the most common opportunistic infection. Disseminated 
tuberculosis and pneumocystis pneumonia and CMV retinitis had the least CD4 
values.
Pruritic  skin  lesions,  anemia,  hepatosplenomegaly  and  lymphadenopathy  and 
tuberculosis were commonly noticed  in older children. Serious life threatening illness 
like pyogenic meningitis,  recurrent bronchopneumonia, pneumocystis pneumonia  and 
recurrent diarrhea were observed  in preschoolers and infants.
 Tuberculosis was present in 54 cases. (pulmonary 21, extrapulmonary 33). Out 
of  33  extra-pulmonary,  30  were  TB  lymphadenopathy,2  were  TB  meningitis,  1 
Disseminated TB.  Out  of  54  Tuberculosis  cases,  manteaux was positive  in  21 cases, 
sputum  positive for AFB in 2 cases. 5 out of 15 deaths were (33% mortality) due to 
tuberculosis. (overall mortality 4.2% ).
134 children, in whom  Antiretroviral therapy was started  & followed up for 
atleast 6 months, 119 were alive and on follow up. 
There were 15 deaths. The median age at ART initiation was 54 months, with 
6 children (9.9%) younger than 11 months, 27 (28.6%) aged 11 to 36 months, and 
33 (36-59 months),68 children (60 months –15 yrs ).
  Of those 134 ( WHO stage II – 18 , stage III- 54, stage IV -62), who  started 
on ART, the median age was 4.5 yrs, 81 were male and 53 were female. The mean 
weight(SD)at the baseline was14.3 (6.64) and increased to 16.58 (7.19) at the last 
follow up visit. The mean CD4 cell ( SD) percentage at ART initiation among the 
119 children was 13.47(4.25) % and increased to 25.51(6.9)% at the last follow up. 
Median Hemoglobin  was 8.6   at the base line and 9.4 gm %  at the last visit . 
Fifteen children died over 2 years of follow-up. Two children failed to respond to 
first  line  ART  regimen  and  were  considered  as  treatment  failure.  They  were 
referred for second line ART regimen. 
In our study, Out of 134 children starting ART,102(76.11%) began stavudine plus 
lamivudine  plus  nevirapine,  3(2.2%)  began  zidovudine  plus  lamivudine  plus 
nevirapine, 2 (1.49%) began zidovudine plus lamivudine plus efavirenz, and 27 
(20.14%) began stavudine plus lamivudine plus efavirenz because 27 cases were 
screened positive  for  tuberculosis  initially.   Of   patients  starting a  nevirapine-
based regimen,  4   were switched to efavirenz ,because  of  allergy.  Of   patients 
starting  a  Zidovudine-based  regimen,  2  were  switched  to  stavudine,  as  they 
developed anemia.
Thirteen patients (9.7%) had adverse effects related to the ART. 4(2.9%) patient 
had severe gastritis. (1 on Zidovudine and 3 on stavudine regimen) initially which 
subsided  with  treatment.  Two  patients  (1.4%)  had  hepatotoxicity  which 
succumbed due to TB meningitis. 2 patient (1.4%) had zidovudine (AZT) induced 
anemia, 4 patients (2.9%) had Nevirapine (NVP) induced rash, 1 patient (0.7%) 
had Stavudine (d4T) induced Peripheral neuropathy.
 Out of 355 children, 15 (4.2%) died,. Children who died were younger compared 
to those who survived, (median age, 36 months vs 60 months; P < .001), had lower 
mean weight  (10.0  vs  13.96   P < .001),  had  lower  baseline  median  hemoglobin 
concentration (8.4 g/dL vs 9.2 g/dL; P < .001), were more likely to be WHO clinical 
stage   IV  (100%  vs  14%,  P < .001),  had  lower  baseline  CD4  values  (15.7% 
vs18.8%)  compared  to  those  who  survived.   Mortality  was  associated  with 
younger  age,  lower  weight-for-age,   anemia   WHO  stage  IV   and  CD4  cell 
depletion
                                                  TABLE I  
DEMOGRAPHIC PROFILE OF HIV INFECTED CHILDREN
Variables Number
Mean 
CD4%
±SD
WHO classification immunodeficiency
Not significant Mild Advanced Severe
Gender
Male 199(56.05) 18.8 52(26.1) 64(32.1) 43(21.6) 40(20.1)
Female 156(43.94) 21.5 60(38.4) 45(28.8) 25(16.0) 26(16.6)
Age in 
years
0<1 yr 45( 2.67) 21.0±2.69 21(46.6) 20(44.4) 2(4.4) 2(4.4)
1 <3yr 95(26.76) 21.6±7.6 44 (46.31) 24(25.26) 14(14.73) 13(13.68)
3 <6yr 92(25.91) 18.9± 8.2 34 (36.95) 25(27.17) 16(17.39) 17(18.47)
6<9yr 41(11.54) 17.2± 9.5 11(26.82) 4 (9.7) 17(41.46) 9 (21.95)
9 <12yr 48(13.52) 15.8± 6.9 15 (31.25) 11(22.91) 14(29.16) 8(16.66)
12 <15yr 34 (9.57) 12.3± 4.5 9(26.47) 5(14.70) 11(32.35) 9(26.47)
TABLE II
CD4 CORRELATION WITH CLINICAL PROFILE OF HIV INFECTED 
CHILDREN
Variables Number Mean CD4%±SD
WHO clinical staging
I 121(34.08%) 26.9±10.2
II 114(32.11%) 20.4±6.4
III 54(15.21%) 16.0±8.2
IV 66(18.59%) 12.6±9.0
PEM** (IAP grading)
  Grade I 56(15.77%) 24.2±8.1
  Grade II 99(27.88%) 22.7±8.2
  Grade III 75(21.12%) 14.8± 9.4
  Grade IV 62 (17.46%) 10.2±6.7
Oppurtunistic infections Number Mean CD4%±SD
    Anaemia Hb %
        >  14
     12 – 14
     10 – 12
     8  - 10     
       <8   
10 (2.8%)
36(10.1%)
72 (20.3%)
232(65.3%)
5 (1.4%)
36±6.2
32±6.2
26±8.2
24±8.4
12.0±3.4
Tuberculous lymphadenopathy :  30(8.4%) 26±8.6
lymphadenopathy 78(21.9%) 32±7.2
Thrombocytopenia 1(0.2%) 12
papullar pruritic eruptions :        53(14.9%) 36±11.2
 viral warts : 20(5.6%) 28±8.6
Molluscum contagiosum                     22(6.1%) 11±5.4
Seborrhoeic Dermatitis 20 (5.6%) 26±6.2
Scabies 17(4.7%) 26±7.4
Chicken pox 14(3.9%) 16±5.6
Herpes zoster 7(1.9%) 24±7.4
Ulcerative gingivitis/periodontitis      28(7.8%) 14±6.2
 Oral candidiasis                               18(5.0%) 9±7.2
Chronic parotitis 12 (2.5%) 20+3
 Chronic /Recurrent Diarrhoea 91(25.6%) 22±8.4
Hepatosplenomegaly 79(22.2%) 21±8.1
Cryptosporidiasis 16(4.5%) 11±6.2
Pulmonary Tuberculosis 21(5.9%) 16±7.4
Bacterial Pneumonia 30(8.4%) 18±8.4
Pneumocystis carinii pneumonia 2(0.5%) 3.5±0.5
Lymphoid interstitial pneumonia 1 (0.2%) 15.5
Chronic lung disease 3(0.8%) 12+2
CSOM/Otorrhoea 46(12.9%) 25±5.5
Recurrent Upper Resp. Infection 96(27.0%) 24±6.4
Tuberculous Meningitis 2(0.5%) 8±2.0
Pyogenic Meningitis 2(0.5%) 12±2.0
HIVEncephalopathy/Developmentaldelay 10(2.8%) 10±2.5
CMV Retinits 2(0.5%) 5±0.5
Cardiomyopathy 1 (0.28%) 12.4
Table-III 
COMPARISON  OF CD4 BEFORE  AND AFTER ART
Before 
treatment 
(n=134)
At followup 
(n=119)
p- value
Mean CD4 
count
427(306) 1095(470) 0.001
Mean CD4 % 13.47(4.25) 25.5(6.90) 0.001
Median hb 8.6 9.4 0.001
 
Table-4
AGE WISE CHANGE IN WEIGHT AND CD4 COUNT AFTER ART
 Initial At follow up            p-value
Age <11months
Weight 5.66(1.15) 6.75(0.66) 0.23 
CD4 count 1076 (284.02) 1545  (478.5) 0.31 
CD4% 19.94(7.10) 31 (7.93) 0.11 
Age12-36month
Weight 7.48 (2.023) 9.26(1.932) 0.0001 
CD4 count 750.64(299) 1306(356) 0.0001 
CD4% 16.28    (3,37) 25.9 (4.9)              0.0001 
Age36-59months
Weight 11.72   (2.19) 14.13 (2.48) 0.0001 
CD4count 411.76(132.7) 1206.31(518.6) 0.0001 
CD4% 13.16 (3.08) 27.13(4.65)  0.0001
Age>60months
Weight      19.45 (5.83)              22.18  (6.2)              0.0001
CD4      241.5(12)             1065(350.64)              0.0001
CD4%      11.97(3)              27.48(5.1)              0.0001
Table – 5
AGE WISE MORTALITY
AGE GROUP
(n) 6 months
Survival
Mortality 
(%)
11 months 6 50% 3    (50%)
11 to 35 months 27 71% 8    (29.6%)
36-59 months 33 97% 1    (3.0%)
60 mon –15 yr 68 95.6% 3     (4.4%)
Table -6
FACTORS ASSOCIATED WITH MORTALITY
Death Survived p value
Rate 4.2% 95.2% 0.001
Median age (months)
at presentation
36 60 0.001
Mean weight 10.0 13.96 0.001
Baseline Hb gm 8.4 9.2 0.001
WHO stage iv 100% 14% 0.001
Baseline CD4% 15.7% 18.8% 0.001
DISCUSSION
This  prospective  cross-sectional  study  has  analysed  the  clinical  profile  in 
relation to CD4 status in HIV infected children attending our ART centre. 
Clinical features in HIV-infected children in our study had some similarities and 
few differences from the previous Indian studies(20,21,22,23,24,25,26). 
Table 6and 7 compare demographic data and clinical features of our study with 
those of previously reported Indian studies. 
Demo 
graphic
Daga
data et 
al. (12)
Dhurat
et al. (4)
Lodha
et al. 
(13)
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nt
et al. (5)
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et al. (7)
Madhi 
vanan
et al. (8)
our
Total 
number
28 55 27 285 24 58 355
Males 18 
(64.3%)
28 
(50.9%)
20 
(74.1%)
– 13 
(54.2%)
39 
(67.2%)
199 
(56%)
Females 10 
(35.7%)
27 
(49.1%)
7 
(25.9%)
– 11 
(45.8%)
19 
(32.8%)
156 
(44%)
Mean 
age at 
Presen 
tation 
10 
months
2month–
13ys
4.5 ys 213 
(74.7%)
4 years 4.5 yrs
Follow-
up
10–18 
months
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Table 7-Comparison of demographic data of pediatric HIV infection 
COMPARISION OF CLINICAL PROFILE WITH OTHER STUDIES
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Our study
Tuberculosis 08 
(28.5%)
27
 (49%)
13 
(48.1%)
84
 (29.4%)
11 
(45.8%)
24 
(41.37%)
54
(15.2%)
MT positivity 04 0 – – – - 21
PCP – – – 11 
(3.8%)
– 2 (3.44%) 2
Oral candidiasis 06
 (21.4%)
13
 (23.6%)
08 
(29.6%)
42 
(14.7%)
13
 (54.1%)
– 48
(13.5%)
Severe PEM 
(IAP grades III 
& IV)
(60.7%)
19 
(34.5%)
22
 (81.4%)
127
 (44.5%)
19 
(79.1%)
10 
(17.24%)
13 7
 (35.5%)
Skin manifstn. 03 
(10.7%)
16 
(29%)
_ 63
(22.1%)
_ _ 92
(25.9%)
Hepato 
Splenomegaly
– 20
 (36.3%)
18
 (66.6%)
82 
(28.7%)
_ 8 
(13.79%)
77
(21.6%)
Generalized –
lymph 
adenopathy
_ 13
 (23.6%)
09
 (33.3%)
67
 (23.5%)
_ 8
 (13.79%)
78
(22%)
HIV 
encephalopathy/ 
CNS 
involvement
_  03 
(11.1%)
13
 (4.5%) 
- 14 
(3.9%)
Fever – _ 21
 (77.7%)
36 
(12.6%)
_ – 149
(42%)
Death 10
 (35.7%)
14
 (25.4%) 
_ 30
 (10.5%)
8
 (13.79%)
15
(4.2%)
Age at death 
Median:
Median:
18 months
8.5 months 
in 
perinatally
acquired
(0.3 months
to 2 years
_ _ _ _
1.75yrs  (range 
6 months -7 
years)
Causes of death 04-
Multiorgan 
failure
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_
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05-
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TB 03- 
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osis02-gr-IV 
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02-PCP
02-Fungal 
sepsis
HIV 
encephal-04 
pyogenic 
meningit-03
TB mening-02
Pneumonia(inc
luding one 
TB)& sepsis 
-05
Chronic lung 
disease -1
As in the previous series, perinatal transmission was the most common mode of 
transmission in our study. HIV acquired via sexual abuse has been reported previously 
(21) but was not encountered by us.
Daga et al(25)reported the presence of known HIV infection in one/both parents 
in 7 cases. 
Growth retardation is a common feature in HIV infected children. Weight gain 
has been used as a parameter in assessing the improvement in clinical status in many 
studies(14). Somatic growth has shown to be affected in patients with HIV infection 
(28).  82% of our children had some degree of PEM (Grade I to IV of IAP).  137 
children  (39%) in  our  series  had  severe  malnutrition  (grade  III/IV)  and 155 others 
(43%) had mild malnutrition (grade I/II). This may be caused by various factors such as 
poor nutrition, neglect, poverty, repeated infections, etc. Malnutrition has been reported 
to be the most common manifestation in HIV-infected children (21,22,23).
Hepatomegaly was seen in 22% of our cases and was one of the most common 
manifestations in our study. Hepatomegaly can be caused by the replication of the HIV 
within  the  reticuloendothelial  system  and  early  onset  lymphadenopathy  and 
hepatomegaly in the first 3 months of life is associated with rapid disease progression 
(28). Hepatosplenomegaly was seen in 28.7% of cases in the study by Merchant et al. 
(22) and in 36% of the cases studied by Dhurat et al. (21).
Generalized lymphadenopathy was seen in 22% of our patients and may have 
been  the  result  of  viral  infections  (such  as  Epstein-Barr  virus  or  cytomegalovirus), 
opportunistic infections, and mycobacterial infections apart from being caused by the 
HIV infection (28). Persistent generalized lymphadenopathy has been seen in 23.5% of 
cases by Merchant et al. (22).
In the present study, diarrhea was the presenting manifestation in 22% children,. 
Infections  causing  diarrhea  in  HIVinfected  children  include  rotavirus,  Shigellae, 
Campylobacter,  E.  coli,  cryptosporidiosis,  isosporiasis,  cytomegalovirus and atypical 
mycobacteria  (22,28).  Cryptosporidiosis  was  reported  in  16  cases.Chronic/recurrent 
diarrhea has been seen in 15 to 43% cases in various studies 22,23,25 )
We encountered tuberculosis in 54 cases (15%). (pulmonary  21, extrapulmonary 33). Out 
of  33  extra-pulmonary,  30  were  TB  lymphadenopathy,  2  were  TB  meningitis  ,1 
Disseminated TB.  Out  of  54  Tuberculosis  cases,  manteaux was positive  in  21 cases, 
sputum  positive for  AFB in 2 cases.   Pulmonary tuberculosis occurred between wide 
range of CD4 values ranging from 2% to 30%.  TB meningitis occurred with low CD4 
values (4% to 12%). 
Tuberculosis in various forms—pulmonary and extrapulmonary has been reported 
commonly  in  HIV-infected  children(21,22,23,25,26)  One  cannot  depend  on  the 
Mantoux (tuberculin) test as it may be falsely negative in patients with HIV (25). Only 
four of eight children diagnosed to have tuberculosis had positive Mantoux test in the 
study by Daga et al. (25). Twenty one patients had positive Mantoux test in our study. 
As in other studies, lack of culture facilities have made it difficult for us to study the 
presence of atypical mycobacteria and resistance pattern in HIV-infected children (22). 
Merchant et al. reported 84 cases (29.4%) with tuberculosis in a cohort of 285 cases; of 
whom 48 had pulmonary lesions, 21 had disseminated tuberculosis, 8 had tubercular 
lymphadenopathy  and  7  had  neurotuberculosis  (22).  Dhurat  et  al.  have  reported 
pulmonary  tuberculosis  in  16  cases,  9  extrapulmonary  (of  whom 4  had  pulmonary 
tuberculosis  as  well;  extrapulmonary  sites:  abdominal-4,  neurotuberculosis-  2  and 
lymphadenopathy-3 cases) (21). A similar spectrum of tubercular manifestations was 
seen in our study as well.
3 cases of  Bronchiectasis were  encountered in our study (4,5,9),as reported in 
earlier  studies.  Bronchiectasis  occurred  when  the  CD4  is  around  12%  (severe 
immunosuppression).  
Pneumocystic carinii pneumonia was less common in our study. Pneumocystis 
carinii pneumonia (PCP) was present in two cases. Merchant et al. have reported 11 
cases of PCP (22).  A low incidence of PCP has been reported among our children . 
Whether  the  apparent  differences  in  the  occurrence  of  P.  carinii  pneumonia  reflect 
difficulties  in  establishing  the  diagnosis,  differences  in  disease  susceptibility  or 
geographic variation in the prevalence of the organism needs to be explored. 
Lymphoid interstitial pneumonia was seen in only one patient in our study. 
Dermatological manifestations were common in our study(26%). Papular pruritic 
eruptions  (15%)  were  the  most  common  skin  lesion  encountered  in  our  study. 
Seborrheic dermatitis(5.6%),  scabies(4.7%), drug eruptions, and skin lesions associated 
with  nutritional  deficiencies,  herpes  zoster(2%),  molluscum contagiosum(6%),  viral 
warts(5.6%)  were  also  noted.  PPE  occurred  in  CD4  ranging  from  (25  to  36%). 
Mollucum contagiosum had the lowest CD4 (11%) compared to all  other cutaneous 
conditions.   Skin  lesions  including  herpes  zoster  (19  cases),  chronic  nonspecific 
dermatitis (20 cases), scabies (18 cases), pyoderma (15 cases), molluscum contagiosum 
(3 cases) and chronic paronychia (2 cases) have been reported by Merchant et al. (22). 
Similarly, Dhurat et al. have reported seborrheic dermatitis (6 cases), chicken pox (4 
cases; hemorrhagic in 2 cases) and herpes zoster (2 cases) (21). 
Anemia was seen in 66% of cases in our study. The causes may include bone 
marrow changes  consistent  with  anemia  of  chronic  disorders,  nutritional  deficiency 
(folic acid or vitamin B12), adverse effects of medications and peripheral destruction of 
erythrocytes  (28).  Anemia  has  been noted  in  symptomatic  patients  in  the  study  by 
Dhurat et al. (21) (32%) and Merchant et al. (22). Thrombocytopenia  was reported in 
one case.
HIV-encephalopathy has been reported in up to 21% of cases with HIV infection 
in other studies (28).  Merchant et al. had 13 cases with HIV encephalopathy in their 
series (22).  3%  of our patients  had HIV-encephalopathy. The neuroimaging features 
(cerebral atrophy, infarction, calcification) were also consistent with the diagnosis of 
encephalopathy  in  these  patients.  Clinical  and  neuroimaging  features  of  HIV-
encephalopathy were similar to the studies reported earlier (22,29). Presence of HIV-
encephalopathy is associated with poor outcome for survival (22,29).
Cardiomyopathy was seen in one case in the present study. One case of immune 
reconstitution syndrome was encountered and managed appropriately.
12 cases of  parotitis were encountered in our study. All oral conditions occurred 
in CD4 range of moderate immuno deficiency (15-25%), except oral candidiasis which 
occurred in CD4 values of severe immunodeficiency.
As  in  some  of  the  previous  studies,  no  cases  with  renal  manifestations  and 
malignancies were reported in our study (21,22,28) 
CD4 count was used as a measure of Immunological outcome in previous 
studies.(31,32)WHO  & national  guidelines  advise  that  clinicians  use  CD4 cell 
percentage for assessment of children younger than 60 months and absolute CD4 
cell count for children 60 months or older. Significant improvement in the CD4 
count and CD4% in response to ART illustrated in our study is in accordance with 
previous studies.(31,32)
Thirteen patients (9.7%) had adverse effects related to the ART. 4(2.9%) 
patient  had severe gastritis.(1 on Zidovudine and 3 on stavudine regimen) initially 
which subsided with treatment.  Two patients  (1.4%) had hepatotoxicity  which 
succumbed due to TB meningitis. 2 patient (1.4%) had zidovudine (AZT) induced 
anemia, 4 patients (2.9%) had Nevirapine (NVP) induced rash, , 1 patient (0.7%) 
had Stavudine (d4T) induced Peripheral neuropathy. Hepatotoxicity was far less 
in the present study in view of close monitoring and careful selection of cases. This 
is  in  contrast  to  previous  Indian  study  which  reported  high  incidence  of 
hepatotoxicity.(33)
Table -9
   COMPARISION OF DRUG TOXICITIES WITH OTHER INDIAN STUDY
Toxicity Drug Present 
study(%)
Irashahetal 
mum2005(%)
incidence OVERALL 9.7 30
gastritis zidovudine 2.9 -
hepatotoxici Stavu/nevi 1.4 16
anemia zidovudine 1.4 12
Rash/SJS nevirapine 2.9 9
Peri.neurop. Stavudine 0.7 -
Out of 355 children, 15 (4.2%) died,. Children who died were younger compared 
to those who survived, (median age, 36 months vs 60 months; P < .001), had lower 
mean weight  (10.0  vs  13.96   P < .001),  had  lower  baseline  median  hemoglobin 
concentration (8.4 g/dL vs 9.2 g/dL; P < .001), were more likely to be WHO clinical 
stage   IV  (100%  vs  14%,  P < .001),  had  lower  baseline  CD4  values  (15.7% 
vs18.8%)  compared  to  those  who  survived.   Mortality  was  associated  with 
younger  age,  lower  weight-for-age,   anemia   WHO  stage  IV   and  CD4  cell 
depletion
Mortality has been variably reported to be 10.5% (22), 25.4% (21) and 35.7% 
(25)  in  various  studies.  Fifteen   of  our  patients  (4.2%)  died  in  our  study.  These 
differences in figures may reflect the differences in the clinical manifestations, early 
versus late  presentations,  duration of follow-up,  presence of  opportunistic  infection, 
appropriate  intervention  with  antiretroviral  therapy,  availability  of  ancillary  and 
supportive care, nutritional support etc. in our centre.
CONCLUSION
 HIV disease in children has a diverse range of manifestations in multiple 
organ systems. 
 Fever  is  the  most  common  initial  presentation  in  children  followed  by 
cough and diarrhoea.
 Pulmonary  tuberculosis  is  the  most  common  opportunistic  infection 
followed by oral candidiasis.
 Meningitis,  CMV  retinitis,  Pneumocystis  carinii  pneumonia,oral 
candidiasis, grade IV malnutrition, WHO class IV symptoms  correlate with 
very low CD4%.
 Treatment with ART results in improvement in CD4%. 
 Mortality is associated with  younger age, lower weight-for-age,  anemia, 
WHO stage IV  and CD4 cell depletion
LIMITATIONS
 Viral  assays  which  remains  the  most  sensitive  indicator  of  response  to 
antiretroviral therapy could not be done because of cost concerns.
 Protease inhibitor-based therapy remains very expensive and unaffordable to our 
patients.
RECOMMENDATIONS
 To suspect and  recognize symptoms & signs of HIV early in infancy to start 
ART earlier.
 Early institution of ART in infancy to reduce underfive mortality due to HIV.
 In the new era of generic HAART, physicians must be trained to identify and 
manage the toxicities associated with HAART .
 Interventions should focus on both child and caregivers and must address social 
problems that adversely affect adherence.
 Physicians  and  health  care  professionals  should  be  taught  about  Universal 
precautions and post-exposure prophylaxis
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                                  ANNEXURE
WHO Clinical Staging of HIV for Infants and Children with Confirmed 
HIV Infection
 Clinical Stage 1
Asymptomatic
Persistent generalized lymphadenopathy
Clinical Stage 2
Unexplained persistent hepatosplenomegaly
Papular pruritic eruptions
Extensive wart virus infection
Extensive molluscum contagiosum
Recurrent oral ulcerations
Unexplained persistent parotid enlargement
Lineal gingival erythema
Herpes zoster
Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, 
tonsillitis )
Fungal nail infections
Clinical Stage 3
Unexplainedi moderate malnutrition not adequately responding to standard therapy
Unexplained persistent diarrhoea (14 days or more )
Unexplained persistent fever (above 37.5oC intermittent or constant, for longer than 
one month)
Persistent oral candidiasis(after  6-8 weeks of age)
Oral hairy leukoplakia
Acute necrotizing ulcerative gingivitis/periodontitis
Lymph node TB
Pulmonary TB
Severe recurrent bacterial pneumonia
Symptomatic lymphoid interstitial pneumonitis
Chronic HIV-associated lung disease including bronchiectasis
Unexplained anemia(<8gm/dl, neutropenia(<0.5×109/l,thrombocytopenia(50×109/l)
Clinical Stage 4
Unexplained severe wasting, stunting or severe malnutrition not responding to standard 
therapy
Pneumocystis pneumonia
Recurrent  severe  bacterial  infections  (e.g.  empyema,  pyomyositis,  bone  or  joint 
infection, meningitis, but excluding pneumonia)
Chronic herpes simplex infection; (orolabial or cutaneous of more than one month’s 
duration or visceral at any site)
Extrapulmonary TB
Kaposi sarcoma
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
Central nervous system toxoplasmosis (after one month of life)
HIV encephalopathy
Cytomegalovirus infection:  retinitis  or  CMV infection affecting another  organ,  with 
onset at age over 1 month.
Extrapulmonary cryptococcosis (including meningitis)
Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis)
Chronic cryptosporidiosis
Chronic isosporiasis
Disseminated non-tuberculous mycobacteria infection
Cerebral or B cell non-Hodgkin lymphoma
Progressive multifocal leukoencephalopathy
Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy

